Catalent (NYSE:CTLT) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Catalent (NYSE:CTLT) in a report published on Tuesday. The firm issued a hold rating on the stock.

Catalent Price Performance

CTLT opened at $63.48 on Tuesday. Catalent has a one year low of $41.15 and a one year high of $63.50. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51. The stock has a market capitalization of $11.52 billion, a P/E ratio of -28.09, a price-to-earnings-growth ratio of 2.69 and a beta of 1.15. The business’s 50-day simple moving average is $62.78 and its 200-day simple moving average is $60.73.

Catalent (NYSE:CTLT) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The firm had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.06 billion. During the same quarter in the prior year, the business earned ($0.10) EPS. The company’s quarterly revenue was up 4.2% compared to the same quarter last year. Analysts anticipate that Catalent will post 0.78 EPS for the current year.

Insider Buying and Selling

In other news, Director Michelle R. Ryan sold 2,800 shares of the company’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the completion of the sale, the director now directly owns 10,835 shares of the company’s stock, valued at approximately $646,849.50. This represents a 20.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.31% of the stock is owned by company insiders.

Hedge Funds Weigh In On Catalent

Several institutional investors have recently added to or reduced their stakes in the stock. Brooklyn Investment Group purchased a new position in shares of Catalent in the 3rd quarter valued at approximately $31,000. Blue Trust Inc. grew its position in Catalent by 88.7% in the 4th quarter. Blue Trust Inc. now owns 615 shares of the company’s stock valued at $37,000 after buying an additional 289 shares during the last quarter. Sentry Investment Management LLC acquired a new position in Catalent in the 3rd quarter valued at $53,000. Thurston Springer Miller Herd & Titak Inc. raised its position in Catalent by 57.5% during the 3rd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,181 shares of the company’s stock worth $72,000 after buying an additional 431 shares during the last quarter. Finally, Intact Investment Management Inc. acquired a new stake in shares of Catalent in the 3rd quarter worth $73,000.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.